Nature Medicine

Papers
(The H4-Index of Nature Medicine is 177. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-06-01 to 2024-06-01.)
ArticleCitations
Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection3114
Post-acute COVID-19 syndrome3035
Extrapulmonary manifestations of COVID-192207
Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections2190
A global survey of potential acceptance of a COVID-19 vaccine1826
An inflammatory cytokine signature predicts COVID-19 severity and survival1803
Attributes and predictors of long COVID1603
Age-dependent effects in the transmission and control of COVID-19 epidemics1311
A single-cell atlas of the peripheral immune response in patients with severe COVID-191238
Long-term cardiovascular outcomes of COVID-191091
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection839
SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma828
Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies775
AI in health and medicine756
A dynamic COVID-19 immune signature includes associations with poor prognosis723
Digital technologies in the public-health response to COVID-19700
COVID-19 vaccine acceptance and hesitancy in low- and middle-income countries675
Seasonal coronavirus protective immunity is short-lasting592
Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies587
Health systems resilience in managing the COVID-19 pandemic: lessons from 28 countries551
An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies543
SARS-CoV-2 infection of the oral cavity and saliva517
Microbiome connections with host metabolism and habitual diet from 1,098 deeply phenotyped individuals494
Targeting metastatic cancer491
Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2488
Immune determinants of COVID-19 disease presentation and severity487
Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera486
Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination477
Clustering and superspreading potential of SARS-CoV-2 infections in Hong Kong475
Determinants of COVID-19 disease severity in patients with cancer470
Long COVID after breakthrough SARS-CoV-2 infection469
Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda464
Symptoms and risk factors for long COVID in non-hospitalized adults463
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial461
Single-cell multi-omics analysis of the immune response in COVID-19456
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study447
Long COVID in a prospective cohort of home-isolated patients445
Looking beyond COVID-19 vaccine phase 3 trials445
Biomarkers for neurodegenerative diseases441
Phylogenomic characterization and signs of microevolution in the 2022 multi-country outbreak of monkeypox virus440
Understanding COVID-19 vaccine hesitancy435
Human postprandial responses to food and potential for precision nutrition431
Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa430
Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein415
Intratumoral heterogeneity in cancer progression and response to immunotherapy411
Human–computer collaboration for skin cancer recognition400
Toward personalized treatment approaches for non-small-cell lung cancer395
Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine389
Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK389
Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection388
Large language models in medicine386
Deep learning in histopathology: the path to the clinic386
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial385
Four distinct trajectories of tau deposition identified in Alzheimer’s disease383
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes374
Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants369
CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer369
Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy365
A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer365
Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI extension361
Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19360
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial352
Partial recovery of visual function in a blind patient after optogenetic therapy351
Brown adipose tissue is associated with cardiometabolic health351
Rapid pathogen detection by metagenomic next-generation sequencing of infected body fluids346
Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial344
Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination339
Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas338
Convalescent plasma treatment of severe COVID-19: a propensity score–matched control study337
Disease and healthcare burden of COVID-19 in the United States337
Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis336
Distinct synovial tissue macrophage subsets regulate inflammation and remission in rheumatoid arthritis332
Modeling COVID-19 scenarios for the United States331
BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar326
Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant325
mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar325
Federated learning for predicting clinical outcomes in patients with COVID-19323
Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China321
Sixteen novel lineages of SARS-CoV-2 in South Africa318
Wearable sensor data and self-reported symptoms for COVID-19 detection317
The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial317
Cellular senescence and senolytics: the path to the clinic316
Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination316
Peripheral immunophenotypes in children with multisystem inflammatory syndrome associated with SARS-CoV-2 infection313
Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus311
Single-cell transcriptomic atlas of the human endometrium during the menstrual cycle309
Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination303
SARS-CoV-2 variants of concern are emerging in India300
mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant298
Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial297
CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial293
Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England293
Magnitude, demographics and dynamics of the effect of the first wave of the COVID-19 pandemic on all-cause mortality in 21 industrialized countries283
Characterization of pre-existing and induced SARS-CoV-2-specific CD8+ T cells283
Minimum information about clinical artificial intelligence modeling: the MI-CLAIM checklist279
Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults279
Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial276
A single-cell landscape of high-grade serous ovarian cancer275
Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination270
COVID-19 in Amazonas, Brazil, was driven by the persistence of endemic lineages and P.1 emergence270
Acute and postacute sequelae associated with SARS-CoV-2 reinfection267
Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters266
Revealing COVID-19 transmission in Australia by SARS-CoV-2 genome sequencing and agent-based modeling266
Tau molecular diversity contributes to clinical heterogeneity in Alzheimer’s disease264
Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma264
Targeting the HIF2–VEGF axis in renal cell carcinoma263
Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals257
Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster257
Unexplained post-acute infection syndromes255
Single-cell meta-analysis of SARS-CoV-2 entry genes across tissues and demographics253
Long-term neurologic outcomes of COVID-19252
Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial252
Guidelines for clinical trial protocols for interventions involving artificial intelligence: the SPIRIT-AI extension250
Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection247
Microglial activation and tau propagate jointly across Braak stages246
Immune complement and coagulation dysfunction in adverse outcomes of SARS-CoV-2 infection244
Rapid SARS-CoV-2 whole-genome sequencing and analysis for informed public health decision-making in the Netherlands243
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses242
Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer241
How medical AI devices are evaluated: limitations and recommendations from an analysis of FDA approvals239
Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies239
Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom239
A stochastic agent-based model of the SARS-CoV-2 epidemic in France238
Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measures238
Underdiagnosis bias of artificial intelligence algorithms applied to chest radiographs in under-served patient populations236
Multimodal biomedical AI235
Responsible use of polygenic risk scores in the clinic: potential benefits, risks and gaps232
Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results231
Closed-loop neuromodulation in an individual with treatment-resistant depression227
Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy227
Vaccine development for emerging infectious diseases225
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial221
A guide to immunotherapy for COVID-19221
Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)221
Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade220
Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies219
The distribution of cellular turnover in the human body218
A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial217
A roadmap to increase diversity in genomic studies216
Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring215
Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern215
Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19215
Clinical outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in Southern California214
Maturation of the gut microbiome during the first year of life contributes to the protective farm effect on childhood asthma210
Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial209
Pathophysiology-based subphenotyping of individuals at elevated risk for type 2 diabetes208
Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma206
Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial204
Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer204
Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma204
IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies203
First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland201
A Neanderthal OAS1 isoform protects individuals of European ancestry against COVID-19 susceptibility and severity200
Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial199
Infectious viral load in unvaccinated and vaccinated individuals infected with ancestral, Delta or Omicron SARS-CoV-2199
PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial196
Articular cartilage regeneration by activated skeletal stem cells196
Robust breast cancer detection in mammography and digital breast tomosynthesis using an annotation-efficient deep learning approach195
Crowding and the shape of COVID-19 epidemics195
Production, safety and efficacy of iPSC-derived mesenchymal stromal cells in acute steroid-resistant graft versus host disease: a phase I, multicenter, open-label, dose-escalation study194
Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma194
Modeling transmission of SARS-CoV-2 Omicron in China190
Increased global integration in the brain after psilocybin therapy for depression189
Using a real-world network to model localized COVID-19 control strategies188
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease188
Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial185
The gut microbiome modulates the protective association between a Mediterranean diet and cardiometabolic disease risk185
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial183
Global maps of travel time to healthcare facilities183
Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial181
Targeting the gut and tumor microbiota in cancer181
Activity-dependent spinal cord neuromodulation rapidly restores trunk and leg motor functions after complete paralysis181
The next phase of SARS-CoV-2 surveillance: real-time molecular epidemiology180
Delayed production of neutralizing antibodies correlates with fatal COVID-19179
Misinformation: susceptibility, spread, and interventions to immunize the public179
Reporting guidelines for human microbiome research: the STORMS checklist178
Viral loads of Delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2177
1.263573884964